View Older Stories View More Recent Stories
-
Deerfield Management and Baylor College of Medicine Announce Blue Square Discoveries to Advance Novel Therapeutic Treatments
-
Miravo Healthcare™ Announces First Quarter 2021 Results
-
DFHT Announces Special Meeting of Stockholders to Vote on Business Combination to be held on June 4, 2021
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
-
Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina
-
Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing
-
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Empire Discovery Institute (EDI) and Deerfield Management Launch Empire-Deerfield Discovery & Development (ED³) LLC
-
Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services
-
Lumos Pharma (LUMO) Announces Retirement of Carl Langren and Names Lori Lawley CFO in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Deerfield Management Announces Winners of the First Annual XSeed Award
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Endologix LLC Announces Acquisition of PQ Bypass, Inc.
-
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
-
Less Than a Year After Official Company Launch, Cohere Health Lands Additional $36 Million in Series B Funding
-
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
-
Vesta Healthcare Announces $65M in Growth Capital to Transform Care for High Needs Members and their Caregivers
-
New Report Authored by Deerfield Management Reveals Vast Gender Gap Across Venture-backed Healthcare Companies
-
Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
-
Deerfield Management, UNC Eshelman School of Pharmacy Announce First Educational Collaboration
-
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Crossover Health Secures $168 Million in Series D Financing to Fuel Expansion of National Primary Health Service
-
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
-
Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial Officer
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Happify Health Raises $73M to Advance and Expand Digital Health Platform
-
Happify Health Raises $73M to Advance and Expand Digital Health Platform
-
Lumos Pharma Inc. (NASDAQ: LUMO) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
-
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
-
Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Xeris Pharmaceuticals (XERS) Prices $27 Million Registered Direct Offering of Common Stock at $4.12/sh
-
Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Coridea and Deerfield to Accelerate Medtech Innovation
-
Dracen Announces Clinical Collaboration with Merck

